🔥 Premium AI-powered Stock Picks from InvestingPro Now up to 50% OffCLAIM SALE

Philippines to seek refund of $59 million from Sanofi amid vaccine risk

Published 08/12/2017, 09:11
Updated 08/12/2017, 09:20
© Reuters. FILE PHOTO: A worker shows used anti-dengue vaccine Dengvaxia inside a vaccine storage room in Sta. Cruz city, Metro Manila
SASY
-

By Manolo Serapio Jr

MANILA (Reuters) - The Philippines will seek the return of 3 billion pesos ($59 million) it paid French drugmaker Sanofi (PA:SASY) for a dengue vaccine used to immunise hundreds of thousands of children that Sanofi has said could worsen the disease in some cases.

"We will demand the refund of the 3 billion (pesos) paid for the Dengvaxia and (demand) that Sanofi set up an indemnification fund to cover the hospitalisation and medical treatment of all children who might have severe dengue," Health Secretary Francisco Duque told reporters on Friday.

The Philippines last week suspended a national immunisation programme after Sanofi's recent findings that there was a risk of severe dengue occurring in previously uninfected people who were inoculated with Dengvaxia. Manila also halted sale of the vaccine in the country and has ordered a probe into the matter.

Duque said the number of children, ages 9 and above, inoculated with Dengvaxia has risen to about 830,000 from an initial estimate of nearly 734,000 after further verification by the Department of Health.

The state programme, which was launched in 2016, cost 3.5 billion pesos and Duque earlier said the government has already paid 3 billion pesos to Sanofi.

Sanofi's Philippines office did not immediately respond to a request for comment.

Sanofi officials said on Monday in Manila that there had been no reported deaths related to the vaccine.

Duque, citing the drugmaker's disclosure and studies, said Dengvaxia was meant to provide 30-month protection against dengue to those vaccinated, including those who did not have any prior dengue infection.

But he said the case of a 12-year old girl in Tarlac province, north of the capital Manila, who completed the three-dose vaccine treatment and showed symptoms of severe dengue, seemed to have defied that.

She was first inoculated with Dengvaxia in March 2016 and received the third and last dose in August this year, the health minister said.

Asked whether the case showed the effectiveness of the vaccine was questionable, Duque said: "Most certainly."

Dengue is a mosquito-borne tropical disease that kills about 20,000 people a year and infects hundreds of millions.

© Reuters. FILE PHOTO: A worker shows used anti-dengue vaccine Dengvaxia inside a vaccine storage room in Sta. Cruz city, Metro Manila

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.